Dallas, Texas / October 31, 2024 — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company specializing in men’s health and wellness products, announced today that it has regained full compliance with the minimum bid price for continued listing on the Nasdaq Stock Market LLC (“Nasdaq”).
On October 30, 2024, Mangoceuticals received a letter from Nasdaq stating that the Company has fulfilled the minimum bid price requirement as per Nasdaq Listing Rule 5550(a)(2). Nasdaq confirmed that for 10 consecutive business days, the closing bid price of Mangoceuticals’ common stock was at or above $1.00 per share, leading to the Company regaining compliance with the stipulated requirement.
In the disclosed press release, Mangoceuticals emphasizes its commitment to innovation and expansion within the men’s health sector. The Company aims to create a strong brand presence in a competitive market while addressing evolving consumer preferences.
While the Company expresses optimism regarding future developments, it acknowledges the existence of potential challenges and uncertainties. Mangoceuticals cautions investors that forward-looking statements are subject to risks and external factors that may impact actual results, including market dynamics, regulatory requirements, and evolving consumer trends.
Interested parties can access comprehensive financial information and detailed reports on Mangoceuticals’ filings with the Securities and Exchange Commission (SEC) at www.sec.gov or the Company’s official website at https://www.mangoceuticals.com/sec-filings.
For further updates and information, individuals can connect with MangoRx on various social media platforms, including Instagram, x.com, and Facebook. Investors seeking additional insights or clarifications are encouraged to reach out to Mangoceuticals’ Investor Relations team via email at [email protected].
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Mangoceuticals’s 8K filing here.
About Mangoceuticals
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Further Reading
- Five stocks we like better than Mangoceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- Battle of the Retailers: Who Comes Out on Top?
- 5 discounted opportunities for dividend growth investors
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Short Selling: How to Short a Stock
- MarketBeat Week in Review – 10/28 – 11/1
